Author Archives: admin


Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer of Inozyme, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 from 2:30-2:55pm ET.

Read the original:
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference

Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel

BioStem Technologies Signs Letter of Intent to Acquire Exclusive US Distribution Rights for revyve™ from ProgenaCare Global BioStem Technologies Signs Letter of Intent to Acquire Exclusive US Distribution Rights for revyve™ from ProgenaCare Global

View post:
Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies…

COPENHAGEN, Denmark, November 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.

Read more:
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies...

Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in Citi’s 2024 Global Healthcare Conference, being held on December 3-5, in Miami, FL.

Read more:
Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will host an investor webcast to provide clinical updates from its RAS(ON) inhibitor portfolio.

Continue reading here:
Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 49,800 shares of the Company’s common stock to four new employees (the “Inducement Grants”) on November 25, 2024 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).

Continued here:
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis

QIAGEN introduces market’s first customizable digital PCR assay design tool with advanced design algorithms tailored for diverse microbial applications and custom NGS panels // First-of-its-kind Custom Assay Design Tool for Microbial dPCR Assays offers unparalleled flexibility in digital PCR analysis of bacterial, fungal and viral targets // QIAseq xHYB Custom Microbial Panels enable high-resolution sequencing by covering multiple whole genomes, overcoming coverage gaps common in standard panels QIAGEN introduces market’s first customizable digital PCR assay design tool with advanced design algorithms tailored for diverse microbial applications and custom NGS panels // First-of-its-kind Custom Assay Design Tool for Microbial dPCR Assays offers unparalleled flexibility in digital PCR analysis of bacterial, fungal and viral targets // QIAseq xHYB Custom Microbial Panels enable high-resolution sequencing by covering multiple whole genomes, overcoming coverage gaps common in standard panels

Read more here:
QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis

Celularity Inc. Announces Receipt of Nasdaq Notification

FLORHAM PARK, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced that on November 21, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company does not comply with the Nasdaq continued listing requirements due to the Company’s inability to timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the “Q3 Form 10-Q”). Nasdaq’s notice has no immediate effect on the listing of Celularity’s common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols “CELU” and “CELUW,” respectively.

Read more:
Celularity Inc. Announces Receipt of Nasdaq Notification

Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.

The rest is here:
Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia